During the past decade, CHU Pellegrin Tripode conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Pellegrin Tripode" #1 sponsor was "Pfizer" with 3 trials, followed by "Centre Hospitalier Departemental Vendee" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "D-Pharm Ltd." with 1 trials sponsored and "Hansa Biopharma AB" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Pellegrin Tripode" #1 collaborator was "Institut National de la Santé Et de la Recherche Médicale, France" with 2 trials as a collaborator, "University Hospital, Tours" with 2 trials as a collaborator, "Biomet France SARL" with 1 trials as a collaborator, "Ministry of Health, France" with 1 trials as a collaborator and "Poitiers University Hospital" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "CHU Pellegrin Tripode" are "Acute Ischemic Stroke" (1 trials), "Acute Respiratory Failure" (1 trials), "Alzheimer Disease" (1 trials), "Ankylosing Spondylitis" (1 trials) and "Anxiety" (1 trials). Many other conditions were trialed in "CHU Pellegrin Tripode" in a lesser frequency.

Most popular intervention types in "CHU Pellegrin Tripode" are "Drug" (7 trials), "Other" (4 trials), "Biological" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "18F Fluorothymidine PET CT" (1 trials), "ATG+mycophénolate mofétil+tacrolimus" (1 trials), "Atazanavir" (1 trials) and "Bapineuzumab 0.5 mg/kg" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHU Pellegrin Tripode" are 15 trials for "All" genders.

Currently, there are NaN active trials in "CHU Pellegrin Tripode". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in CHU Pellegrin Tripode, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Pellegrin Tripode, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".